Skip to main navigation

Top

Skip to main content

About Us

About Us
Rare Diseases

Rare Defined Diseases
Pipeline

Pipeline
Our Medicine

Our Medicine
Patients & Partners

Patients & Partners
Investors

Investors
Inside Agios

Inside Agios

Press Releases

Investors Overview
News & Events
Stock Information
Corporate Governance
Financials
IR Resources

Year

Dec 18, 2024

European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease

Read More

PDF Version

Dec 08, 2024

Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat

Read More

PDF Version

Nov 05, 2024

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition

Read More

PDF Version

Oct 31, 2024

Agios Reports Business Highlights and Third Quarter 2024 Financial Results

Read More

PDF Version

Oct 23, 2024

Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease

Read More

PDF Version

Oct 17, 2024

Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024

Read More

PDF Version

Sep 11, 2024

Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)

Read More

PDF Version

Sep 05, 2024

Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024

Read More

PDF Version

Aug 06, 2024

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

Read More

PDF Version

Aug 01, 2024

Agios Reports Business Highlights and Second Quarter 2024 Financial Results

Read More

PDF Version

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 30

Latest Earnings Call View Replay
Latest Form 10-K View PDF
Email Alerts Sign Up
Corporate Fact Sheet View PDF
Corporate Responsibility View PDF

Connect with us on LinkedIn or follow us on Twitter as we push forward into changing the landscape for people with rare diseases.

Connect on LinkedIn

Follow us our Twitter

Contact
About Us
Partner Opportunities
Careers

Agios Pharmaceuticals, Inc. © 2024

All right reserved.

Cookies Preferences
Copyright Info
Compliance
Sitemap
Privacy Notice
Terms of Use